Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB.

N Engl J Med. 2007 Mar 8;356(10):998-1008. Epub 2007 Feb 12.

2.

The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.

Kumbhani DJ, Bavry AA, Kamdar AR, Helton TJ, Bhatt DL.

Am Heart J. 2008 Apr;155(4):640-7. doi: 10.1016/j.ahj.2007.11.017. Epub 2008 Feb 21. Review.

PMID:
18371470
3.

A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.

Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Jüni P, Pfisterer ME, Meier B, Kastrati A.

J Am Coll Cardiol. 2007 Oct 2;50(14):1373-80. Epub 2007 Aug 21. Review.

4.

The efficacy of sirolimus- and paclitaxel-eluting stents: a meta-analysis of randomized controlled trials.

Kittleson MM, Needham DM, Kim SJ, Ravindran BK, Solomon SS, Guallar E.

Can J Cardiol. 2005 May 15;21(7):581-7. Review.

PMID:
15940356
5.

Drug-eluting stents: from randomized trials to the real world.

Saia F, Degertekin M, Lemos PA, Serruys PW.

Minerva Cardioangiol. 2004 Oct;52(5):349-63. Review.

6.
7.

Drug-eluting stents and stent thrombosis: a cause for concern?

Wernick MH, Jeremias A, Carrozza JP.

Coron Artery Dis. 2006 Dec;17(8):661-5. Review.

PMID:
17119373
8.
9.

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P.

Lancet. 2007 Sep 15;370(9591):937-48. Review.

PMID:
17869634
10.

Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW.

J Am Coll Cardiol. 2014 Feb 4;63(4):299-307. doi: 10.1016/j.jacc.2013.09.061. Epub 2013 Nov 6. Review.

11.

Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.

De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW; Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation.

Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2. doi: 10.1001/archinternmed.2012.758. Review.

PMID:
22529227
12.

Drug eluting stents: an updated meta-analysis of randomised controlled trials.

Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G.

Heart. 2006 May;92(5):641-9. Epub 2005 Oct 10. Review.

13.

Multi-Link Vision stent vs. first-generation drug-eluting stents: systematic review and meta-analysis.

Testa L, Latini RA, Pizzocri S, Lanotte S, Agnifili M, Laudisa ML, Brambilla N, Bedogni F.

QJM. 2011 Dec;104(12):1025-34. doi: 10.1093/qjmed/hcr138. Epub 2011 Sep 6. Review.

15.

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW.

Lancet. 2012 Apr 14;379(9824):1393-402. doi: 10.1016/S0140-6736(12)60324-9. Epub 2012 Mar 23. Review.

PMID:
22445239
16.

Current status of the Xience V® everolimus-eluting coronary stent system.

Claessen BE, Caixeta A, Henriques JP, Piek JJ.

Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1363-74. doi: 10.1586/erc.10.127. Review.

PMID:
20936921
17.

Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials.

Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P.

Heart. 2006 May;92(5):650-7. Epub 2005 Oct 26. Review.

18.

Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.

Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, Sangiorgi D, Bacchi Reggiani L, Kaiser C, Kim HS, De Waha A, Ribichini F, Stone GW.

Circ Cardiovasc Interv. 2012 Jun;5(3):357-64. doi: 10.1161/CIRCINTERVENTIONS.111.967083. Epub 2012 Jun 5. Review.

19.

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V).

Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G.

Vasc Health Risk Manag. 2008;4(1):31-8. Review.

20.

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.

Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P.

BMJ. 2008 Aug 29;337:a1331. doi: 10.1136/bmj.a1331. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk